IGM Biosciences

IGM Biosciences

  • Founded: 2010
  • Location: Mountain View, CA
  • Employee range: 200 - 500
  • Clinical stage: Clin1
  • Therapy area: NHL
  • Drug types: ONC, IMM
  • Lead product: Imvotamab
  • Product link: https://igmbio.com/pipeline/
  • Funding: $120M stock Jun 2023; $230M stock Apr 2022; $230M stock Dec 2020; $175M IPO Sep 2019; $102M C Jul 2019



job board

Short description:

Antibody Treatments

Drug notes:

Also Clin0 autoimmune diseases; IGM-8444 3 trials Clin1 multiple cancers; IGM-7354 Clin1 solid & hematologic malignancies; IGM-2537 Clin0 multiple cancers; undisclosed RD undisclosed

Long description:

IGM Biosciences is pioneering the development of IgM antibodies to treat disease. Current antibody therapies commonly use the Y-shaped IgG structure to bind specific targets; however, the IgM antibody structure may have greater binding power. IgG antibodies possess two binding units, while IgM antibodies have ten. IGM is using this structural baseline to create “super-antibodies” by improving the qualities of IgM antibodies and allowing production at scale. Increased binding avidity and affinity enables IGM to design IgM antibodies to target difficult antigens and also bind multiple targets simultaneously, opening up the translational capabilities of their products to different diseases from cancer to autoimmune. Clinical trials for Non-Hodgkin’s lymphoma are in progress.


IGM Biosciences
Associate Scientist / Scientist, Analytical Develo...
B1 - CA, MVOn-site|22 days ago
IGM Biosciences
Clinical Trial Manager
B5 - CA, MVHybrid|33 days ago
IGM Biosciences
Director, Supply Planning and Project Management
Mountain View, CAOn-site|50 days ago
IGM Biosciences
Plant Engineer / Sr. Plant Engineer, GMP
Mountain View, CAOn-site|85 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com